Drugs & Targets FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer January 19, 2024Vol.50 No.03
Regulatory News Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approvalMeanwhile, NCI trial will assess clinical utility January 12, 2024Vol.50 No.02By Jacquelyn Cobb
Drugs & Targets FDA approves Padcev + Keytruda for locally advanced or metastatic urothelial cancer January 05, 2024Vol.50 No.01
FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals December 15, 2023Vol.49 No.46By Matthew Bin Han Ong
Drugs & Targets FDA approves Iwilfin for adult and pediatric patients with high-risk neuroblastoma December 15, 2023Vol.49 No.46
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation December 08, 2023Vol.49 No.45By Matthew Bin Han Ong
Drugs & Targets FDA grants Fast Track designation to Alpha1H for non-muscle invasive bladder cancer December 08, 2023Vol.49 No.45
